Skip to main content
رجوع
IOVA logo

Iovance Biotherapeutics, Inc.

جودة البيانات: 100%
IOVA
NASDAQ Healthcare Biotechnology
KWD 3.62
▼ KWD 0.01 (-0.28%)
القيمة السوقية: 1.20B
نطاق اليوم
KWD 3.43 KWD 3.68
نطاق 52 أسبوعًا
KWD 1.64 KWD 5.63
حجم التداول
11,794,990
متوسط 50 يوم / 200 يوم
KWD 3.20 / KWD 2.53
الإغلاق السابق
KWD 3.63

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -3.1 0.4
P/B 1.7 2.9
ROE % -55.5 3.7
Net Margin % -148.4 3.9
Rev Growth 5Y % 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 2.000 -44.8%
ربحية السهم المستقبلية
-KWD 0.501
الإيرادات المقدّرة
380 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 0.223
KWD 0.175 – KWD 0.274
870 M 2
FY2029 KWD 0.104
KWD 0.082 – KWD 0.128
790 M 4
FY2028 KWD 0.007
-KWD 0.110 – KWD 0.190
740 M 6

النقاط الرئيسية

Debt/Equity of 0.07 — conservative balance sheet
Negative free cash flow of -336.24M
PEG of 0.17 suggests growth is underpriced

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)60.60%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-55.50%
ROIC-40.50%
Net Margin-148.38%
Op. Margin-153.08%

الأمان

Debt / Equity
0.07
Current Ratio3.20
Interest Coverage0.00

التقييم

P/E Ratio
-3.07
P/B Ratio1.72
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 60.60% Revenue Growth (3Y) 1388.68%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 263.50M Net Income (TTM) -390.98M
ROE -55.50% ROA -42.82%
Gross Margin 97.23% Operating Margin -153.08%
Net Margin -148.38% Free Cash Flow (TTM) -336.24M
ROIC -40.50% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.07 Current Ratio 3.20
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -3.07 P/B Ratio 1.72
P/S Ratio 4.56 PEG Ratio 0.17
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.20B Enterprise Value 1.09B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 263.50M 164.07M 1.19M 0.0 0.0
Net Income -390.98M -372.18M -444.04M -395.89M -342.25M
EPS (Diluted) -1.09 -1.28 -1.89 -2.49 -2.23
Gross Profit 256.22M 40.08M -9.57M 0.0 0.0
Operating Income -403.36M -395.28M -460.56M -398.88M -342.70M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 913.17M 910.43M 780.35M 663.98M 777.33M
Total Liabilities 214.59M 200.02M 195.74M 164.34M 155.67M
Shareholders' Equity 698.58M 710.41M 584.61M 499.64M 621.66M
Total Debt 48.44M 58.26M 75.86M 85.45M 71.53M
Cash & Equivalents 163.08M 115.69M 114.89M 231.73M 78.23M
Current Assets 442.69M 457.02M 307.85M 479.12M 507.96M
Current Liabilities 138.36M 122.34M 110.31M 91.49M 89.20M